Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| FRE-FNCLCC-GETUG-13/0206 | Other Identifier | UNICANCER | |
| 2005-001072-13 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
PURPOSE: This randomized phase III trial is comparing two different combination chemotherapy regimens to see how well they work in treating patients with stage II or stage III non-seminomatous germ cell tumors.
OBJECTIVES:
OUTLINE: This is a randomized, multicenter study.
Patients receive 1 course of bleomycin, etoposide, and cisplatin (BEP). Patients with a favorable decrease of tumor markers after 1 course of BEP receive 3 additional courses of BEP. Patients with an unfavorable decrease of tumor markers after 1 course of BEP are randomized to 1 of 2 treatment arms.
PROJECTED ACCRUAL: A total of 260 patients will be accrued for this study.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm I | Active Comparator | Patients receive 4 courses of bleomycin, etoposide, and cisplatin (BEP). |
|
| Arm II | Experimental | Patients receive 1 course of bleomycin, etoposide, and cisplatin (BEP). Patients then receive dose-dense sequential combination chemotherapy comprising cisplatin, etoposide, bleomycin, paclitaxel, oxaliplatin, and ifosfamide. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| bleomycin sulfate | Biological | At least one course administered |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Progression-free Survival Rate After 1 Course of Treatment | Primary objective is to compare the progression-free survival of participants after 1 cycle of treatment, treated randomly by 3 additional cycles of BEP (Arm I) or by T-BEP-Oxaliplatin/cisplatin-ifosfamide-Bleomycin (Arm II). The median progression-free survival rate was defined as the median percentage of participants alive without disease progression after 1 course of treatment. | 3 years from randomization |
| Measure | Description | Time Frame |
|---|---|---|
| Overall Survival | To evaluated the overall survival in both groups in participants presenting fast and slow decrease in serum levels of tumor markers. The median overall survival was defined as the median percentage of participants alive after 1 course of treatment. | 3 years from randomization |
Not provided
DISEASE CHARACTERISTICS:
Diagnosis of non-seminomatous germ cell tumors (NSGCT) as evidenced by 1 of the following criteria:
Clinical stage II-III disease (disseminated disease)
Testicular, retroperitoneal, or mediastinal primary site
Poor prognosis disease, meeting 1 of the following criteria:
Mediastinal primary site
Non-pulmonary visceral metastases
One of the following lab values:
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Karim Fizazi, MD, PhD | Gustave Roussy, Cancer Campus, Grand Paris | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| M. D. Anderson Cancer Center at University of Texas | Houston | Texas | 77030-4009 | United States | ||
| Centre Paul Papin |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39167741 | Derived | Fizazi K, Le Teuff G, Flechon A, Pagliaro L, Mardiak J, Geoffrois L, Laguerre B, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Cancel M, Juzyna B, Reckova M, Naoun N, Logothetis C, Culine S. Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial. J Clin Oncol. 2024 Oct;42(28):3270-3276. doi: 10.1200/JCO.23.01960. Epub 2024 Aug 21. | |
| 25456363 |
Not provided
Not provided
Individual Participant Data will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.
Not provided
Not provided
Not provided
Not provided
Of the 263 patients registered 255 were evaluated for biomarker decrease after one cycle of BEP. Eight patients were not evaluated for biomarker decrease: 6 patients died early, 1 patient 1 withdrew consent and 1 patient was included by error. 1 patient was not covered by EC approval and excluded froma analysis. The 203 patients with unfavorable decrease in tumor biomarkers were randomized in Arm I (98 patients) or Arm II (105 patients).
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Arm I | Patients receive 4 courses of bleomycin, etoposide, and cisplatin (BEP). bleomycin sulfate: At least one course administered cisplatin: At least one course administered etoposide: At least one course administered |
| FG001 | Arm II |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Phase 3 trial with direct individual benefit, randomized, open-label, multicenter, parallel groups
Not provided
Not provided
Not provided
Not provided
| cisplatin |
| Drug |
At least one course administered |
|
| etoposide | Drug | At least one course administered |
|
| ifosfamide | Drug | Given in a dose-dense sequential fashion |
|
| oxaliplatin | Drug | Given in a dose-dense sequential fashion |
|
| paclitaxel | Drug | Given in a dose-dense sequential fashion |
|
| Angers |
| 49100 |
| France |
| Institut Bergonie | Bordeaux | 33076 | France |
| C.H.U. de Brest | Brest | 29609 | France |
| Centre Regional Francois Baclesse | Caen | 14076 | France |
| CHU de Grenoble - Hopital de la Tronche | Grenoble | 38043 | France |
| Centre Oscar Lambret | Lille | 59020 | France |
| Centre Leon Berard | Lyon | 69008 | France |
| Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes | Marseille | 13273 | France |
| Hopital Notre-Dame de Bon Secours | Metz | 57038 | France |
| Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle | Montpellier | 34298 | France |
| Centre Antoine Lacassagne | Nice | 06189 | France |
| Hopital Europeen Georges Pompidou | Paris | 75015 | France |
| Hopital Tenon | Paris | 75970 | France |
| Institut Jean Godinot | Reims | 51056 | France |
| Centre Eugene Marquis | Rennes | 35042 | France |
| Centre Hospitalier de Rodez | Rodez | 12027 | France |
| Centre Henri Becquerel | Rouen | 76038 | France |
| CRLCC Nantes - Atlantique | Saint-Herblain | 44805 | France |
| Institut Claudius Regaud | Toulouse | 31052 | France |
| Centre Hospitalier Universitaire Bretonneau de Tours | Tours | 37044 | France |
| Centre Alexis Vautrin | Vandœuvre-lès-Nancy | 54511 | France |
| Institut Gustave Roussy | Villejuif | F-94805 | France |
| National Cancer Institute - Bratislava | Bratislava | 833 10 | Slovakia |
| Derived |
| Fizazi K, Pagliaro L, Laplanche A, Flechon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Culine S. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol. 2014 Dec;15(13):1442-1450. doi: 10.1016/S1470-2045(14)70490-5. Epub 2014 Nov 13. |
Patients receive 1 course of bleomycin, etoposide, and cisplatin (BEP). Patients then receive dose-dense sequential combination chemotherapy comprising cisplatin, etoposide, bleomycin, paclitaxel, oxaliplatin, and ifosfamide. bleomycin sulfate: At least one course administered cisplatin: At least one course administered etoposide: At least one course administered ifosfamide: Given in a dose-dense sequential fashion oxaliplatin: Given in a dose-dense sequential fashion paclitaxel: Given in a dose-dense sequential fashion |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Arm I | Patients receive 4 courses of bleomycin, etoposide, and cisplatin (BEP). bleomycin sulfate: At least one course administered cisplatin: At least one course administered etoposide: At least one course administered |
| BG001 | Arm II | Patients receive 1 course of bleomycin, etoposide, and cisplatin (BEP). Patients then receive dose-dense sequential combination chemotherapy comprising cisplatin, etoposide, bleomycin, paclitaxel, oxaliplatin, and ifosfamide. bleomycin sulfate: At least one course administered cisplatin: At least one course administered etoposide: At least one course administered ifosfamide: Given in a dose-dense sequential fashion oxaliplatin: Given in a dose-dense sequential fashion paclitaxel: Given in a dose-dense sequential fashion |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median | Full Range | Years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Progression-free Survival Rate After 1 Course of Treatment | Primary objective is to compare the progression-free survival of participants after 1 cycle of treatment, treated randomly by 3 additional cycles of BEP (Arm I) or by T-BEP-Oxaliplatin/cisplatin-ifosfamide-Bleomycin (Arm II). The median progression-free survival rate was defined as the median percentage of participants alive without disease progression after 1 course of treatment. | The primary endpoint for the study was the comparison of the PFS rates in the population of participants with a poor prognostic non-seminomatous germ cell tumors and with an unfavorable decrease in tumor biomarkers, randomized to either Unfav-BEP Control Arm (Arm I) or Unfav-Dose-Dense Arm (Arm II). | Posted | Number | 95% Confidence Interval | percentage of participants | 3 years from randomization |
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Overall Survival | To evaluated the overall survival in both groups in participants presenting fast and slow decrease in serum levels of tumor markers. The median overall survival was defined as the median percentage of participants alive after 1 course of treatment. | Posted | Number | 95% Confidence Interval | percentage of participants | 3 years from randomization |
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Arm I | Patients receive 4 courses of bleomycin, etoposide, and cisplatin (BEP). bleomycin sulfate: At least one course administered cisplatin: At least one course administered etoposide: At least one course administered | 61 | 98 | 37 | 98 | 98 | 98 |
| EG001 | Arm II | Patients receive 1 course of bleomycin, etoposide, and cisplatin (BEP). Patients then receive dose-dense sequential combination chemotherapy comprising cisplatin, etoposide, bleomycin, paclitaxel, oxaliplatin, and ifosfamide. bleomycin sulfate: At least one course administered cisplatin: At least one course administered etoposide: At least one course administered ifosfamide: Given in a dose-dense sequential fashion oxaliplatin: Given in a dose-dense sequential fashion paclitaxel: Given in a dose-dense sequential fashion | 66 | 105 | 58 | 105 | 105 | 105 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Acute leukemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA | Systematic Assessment |
| |
| Anemia | Blood and lymphatic system disorders | MedDRA | Systematic Assessment |
| |
| Aplasia bone marrow | Blood and lymphatic system disorders | MedDRA | Systematic Assessment |
| |
| Bicytopenia | Blood and lymphatic system disorders | MedDRA | Systematic Assessment |
| |
| Febrile aplasia | Blood and lymphatic system disorders | MedDRA | Systematic Assessment |
| |
| Febrile neutropenia | Blood and lymphatic system disorders | MedDRA | Systematic Assessment |
| |
| Myeloid leukemia, acute | Blood and lymphatic system disorders | MedDRA | Systematic Assessment |
| |
| Granulocytopenia | Blood and lymphatic system disorders | MedDRA | Systematic Assessment |
| |
| Myelodysplasia | Blood and lymphatic system disorders | MedDRA | Systematic Assessment |
| |
| Neutropenia | Blood and lymphatic system disorders | MedDRA | Systematic Assessment |
| |
| Neutropenia aggravated | Blood and lymphatic system disorders | MedDRA | Systematic Assessment |
| |
| Neutropenia malignany | Blood and lymphatic system disorders | MedDRA | Systematic Assessment |
| |
| Thrombopenia | Blood and lymphatic system disorders | MedDRA | Systematic Assessment |
| |
| Pericarditis | Cardiac disorders | MedDRA | Systematic Assessment |
| |
| Abdominal pain | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Fistula of small intestine | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Anal abscess | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Intestinal obstruction | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Mucositis | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Stomatitis | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Fever | General disorders | MedDRA | Systematic Assessment |
| |
| Catheter infection | Injury, poisoning and procedural complications | MedDRA | Systematic Assessment |
| |
| Catheter blocage | Injury, poisoning and procedural complications | MedDRA | Systematic Assessment |
| |
| General physical health deterioration | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Hyperthermia | General disorders | MedDRA | Systematic Assessment |
| |
| Liver damage | Hepatobiliary disorders | MedDRA | Systematic Assessment |
| |
| Infection | Infections and infestations | MedDRA | Systematic Assessment |
| |
| scrotal abscess | Infections and infestations | MedDRA | Systematic Assessment |
| |
| Septicemia | Infections and infestations | MedDRA | Systematic Assessment |
| |
| Sepsis | Infections and infestations | MedDRA | Systematic Assessment |
| |
| vomiting post chemotherapy | Injury, poisoning and procedural complications | MedDRA | Systematic Assessment |
| |
| weight decrease | Investigations | MedDRA | Systematic Assessment |
| |
| Liver enzyme abnormal | Investigations | MedDRA | Systematic Assessment |
| |
| Dehydration | Metabolism and nutrition disorders | MedDRA | Systematic Assessment |
| |
| Diabetes with renal manifestations | Metabolism and nutrition disorders | MedDRA | Systematic Assessment |
| |
| Gout acute | Metabolism and nutrition disorders | MedDRA | Systematic Assessment |
| |
| Malnutrition | Metabolism and nutrition disorders | MedDRA | Systematic Assessment |
| |
| Intervertebral disc compression | Musculoskeletal and connective tissue disorders | MedDRA | Systematic Assessment |
| |
| Lumbar pain | Musculoskeletal and connective tissue disorders | MedDRA | Systematic Assessment |
| |
| Fracture cervical spine | Musculoskeletal and connective tissue disorders | MedDRA | Systematic Assessment |
| |
| Inguinal abscess | Musculoskeletal and connective tissue disorders | MedDRA | Systematic Assessment |
| |
| Melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA | Systematic Assessment |
| |
| Mediastinal neoplasm NOS | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA | Systematic Assessment |
| |
| Tumor progression | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA | Systematic Assessment |
| |
| Coma | Nervous system disorders | MedDRA | Systematic Assessment |
| |
| Convulsions | Nervous system disorders | MedDRA | Systematic Assessment |
| |
| Hypertension intracranial | Nervous system disorders | MedDRA | Systematic Assessment |
| |
| Consciousness loss of | Nervous system disorders | MedDRA | Systematic Assessment |
| |
| Hypoaesthesia | Nervous system disorders | MedDRA | Systematic Assessment |
| |
| Neuropathy | Nervous system disorders | MedDRA | Systematic Assessment |
| |
| Paraesthesia | Nervous system disorders | MedDRA | Systematic Assessment |
| |
| Polyneuropathy toxic | Nervous system disorders | MedDRA | Systematic Assessment |
| |
| Seizure | Nervous system disorders | MedDRA | Systematic Assessment |
| |
| Stroke | Nervous system disorders | MedDRA | Systematic Assessment |
| |
| Anxiety depression | Psychiatric disorders | MedDRA | Systematic Assessment |
| |
| Ureteral stricture | Renal and urinary disorders | MedDRA | Systematic Assessment |
| |
| Renal insufficiency | Renal and urinary disorders | MedDRA | Systematic Assessment |
| |
| Renal failure acute | Renal and urinary disorders | MedDRA | Systematic Assessment |
| |
| Dyspnea | Respiratory, thoracic and mediastinal disorders | MedDRA | Systematic Assessment |
| |
| Hemoptysis | Respiratory, thoracic and mediastinal disorders | MedDRA | Systematic Assessment |
| |
| Obstruction lung disease | Respiratory, thoracic and mediastinal disorders | MedDRA | Systematic Assessment |
| |
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | MedDRA | Systematic Assessment |
| |
| Respiratory distress | Respiratory, thoracic and mediastinal disorders | MedDRA | Systematic Assessment |
| |
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA | Systematic Assessment |
| |
| Bilateral pneumonia | Respiratory, thoracic and mediastinal disorders | MedDRA | Systematic Assessment |
| |
| Bronchospasm | Respiratory, thoracic and mediastinal disorders | MedDRA | Systematic Assessment |
| |
| Mediastinal emphysema | Respiratory, thoracic and mediastinal disorders | MedDRA | Systematic Assessment |
| |
| Pneumopathy | Respiratory, thoracic and mediastinal disorders | MedDRA | Systematic Assessment |
| |
| Platelet transfusion | Surgical and medical procedures | MedDRA | Systematic Assessment |
| |
| Cutaneous hypersensitivity | Skin and subcutaneous tissue disorders | MedDRA | Systematic Assessment |
| |
| Abdominal aortic aneurysm | Vascular disorders | MedDRA | Systematic Assessment |
| |
| Epistaxis | Vascular disorders | MedDRA | Systematic Assessment |
| |
| Intracerebral hemorrhage | Vascular disorders | MedDRA | Systematic Assessment |
| |
| Peritoneal haemorrhage | Vascular disorders | MedDRA | Systematic Assessment |
| |
| Phlebitis lower limb | Vascular disorders | MedDRA | Systematic Assessment |
| |
| Tumor hemorrhage | Vascular disorders | MedDRA | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Rash | Skin and subcutaneous tissue disorders | MedRRA | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Diarrhea | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Mucositis | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Liver function test increased | Hepatobiliary disorders | MedDRA | Systematic Assessment |
| |
| Neuropathy | Nervous system disorders | MedDRA | Systematic Assessment |
| |
| Auditory disorder | Ear and labyrinth disorders | MedDRA | Systematic Assessment |
| |
| Dyspnea | Respiratory, thoracic and mediastinal disorders | MedDRA | Systematic Assessment |
| |
| Creatinine | Hepatobiliary disorders | MedDRA | Systematic Assessment |
| |
| Asthenia | General disorders | MedDRA | Systematic Assessment |
| |
| Infection | Infections and infestations | MedDRA | Systematic Assessment |
| |
| Hemoglobin | Blood and lymphatic system disorders | MedDRA | Systematic Assessment |
| |
| Granulocytes | Blood and lymphatic system disorders | MedDRA | Systematic Assessment |
| |
| Platelets | Blood and lymphatic system disorders | MedDRA | Systematic Assessment |
| |
| Febrile neutropenia | Blood and lymphatic system disorders | MedDRA | Systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Deputy Director R&D | Unicancer | (+33)1 44 23 04 19 | b-juzyna@unicancer.fr |
| ID | Term |
|---|---|
| D013724 | Teratoma |
| C563236 | Testicular Germ Cell Tumor |
| D013736 | Testicular Neoplasms |
| D018236 | Carcinoma, Embryonal |
| D018240 | Endodermal Sinus Tumor |
| ID | Term |
|---|---|
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D004700 | Endocrine System Diseases |
| D013733 | Testicular Diseases |
| D006058 | Gonadal Disorders |
| D008649 | Mesonephroma |
Not provided
Not provided
| ID | Term |
|---|---|
| D001761 | Bleomycin |
| D002945 | Cisplatin |
| D005047 | Etoposide |
| D007069 | Ifosfamide |
| D000077150 | Oxaliplatin |
| D017239 | Paclitaxel |
| ID | Term |
|---|---|
| D006020 | Glycopeptides |
| D006001 | Glycoconjugates |
| D002241 | Carbohydrates |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
| D017672 | Nitrogen Compounds |
| D017671 | Platinum Compounds |
| D011034 | Podophyllotoxin |
| D013764 | Tetrahydronaphthalenes |
| D009281 | Naphthalenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D011083 | Polycyclic Compounds |
| D005960 | Glucosides |
| D006027 | Glycosides |
| D003520 | Cyclophosphamide |
| D010752 | Phosphoramide Mustards |
| D009588 | Nitrogen Mustard Compounds |
| D009150 | Mustard Compounds |
| D006846 | Hydrocarbons, Halogenated |
| D063088 | Phosphoramides |
| D009943 | Organophosphorus Compounds |
| D010078 | Oxazines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D056831 | Coordination Complexes |
| D043823 | Taxoids |
| D043822 | Cyclodecanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D004224 | Diterpenes |
| D013729 | Terpenes |
Not provided
Not provided
| Male |
|
| Slovakia |
|
| France |
|
|
|
|